Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.75 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.73 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6971701 | 0.90 | AGTR1 (0.71) | AGTR1ABCC3ABCC2 | |
| SCHEMBL6971686 | 0.90 | AGTR1 (0.71) | AGTR1ABCC3ABCC2 | |
| SCHEMBL9425862 | 0.89 | AGTR1 (0.61) | AGTR1ABCC3ABCC2 | |
| SCHEMBL9425847 | 0.89 | AGTR1 (0.61) | AGTR1ABCC3ABCC2 | |
| SCHEMBL7277799 | 0.88 | AGTR1 (0.90) | AGTR1ABCC3ABCC2 | |
| SCHEMBL7277792 | 0.88 | AGTR1 (0.90) | AGTR1ABCC3ABCC2 | |
| SCHEMBL7054518 | 0.87 | AGTR1 (0.55) | AGTR1ABCC3ABCC2 | |
| SCHEMBL7054534 | 0.87 | AGTR1 (0.55) | AGTR1ABCC3ABCC2 | |
| SCHEMBL7054525 | 0.87 | AGTR1 (0.55) | AGTR1ABCC3ABCC2 | |
| SCHEMBL16624683 | 0.85 | AGTR1 (0.88) | AGTR1ABCC3ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-0955294-B1 | Imidazolyl-alkenoic acid | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | EP | disclosed |
| EP-0955294-A2 | Imidazolyl-alkenoic acid | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5418250-A | Hypotensive | SMITHKLINE BEECHAM CORPORATION (US) | 1995-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | AGTR1 3252/4885ABCC3 4557/4885ABCC2 4612/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | AGTR1 8/4885ABCC3 4229/4885ABCC2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.